Table 1.
HCT Characteristics of Critically Ill Pediatric Allogeneic HCT Patients
| 1st PICU Admission (n=936) | 2nd PICU Admission (n=404) | 3rd PICU Admission (n=192) | |
|---|---|---|---|
| Age at transplant (median years, IQR) | 8 (2 – 14) | 9 (2 – 14) | 10 (2 – 14) |
| Sex (n, %) | |||
| Male | 548 (59) | 245 (61) | 112 (58) |
| Female | 388 (41) | 159 (39) | 80 (42) |
| Race/Ethnicity (n, %) | |||
| Caucasian, non-Hispanic | 475 (51) | 208 (51) | 108 (56) |
| Caucasian, Hispanic | 149 (16) | 53 (13) | 24 (13) |
| African-American | 176 (19) | 92 (23) | 41 (21) |
| Asian / Pacific Islander | 51 ( 5) | 24 ( 6) | 6 ( 3) |
| Native American | 15 ( 2) | 2 (<1) | 2 ( 1) |
| Unknown | 70 ( 7) | 25 ( 6) | 11 ( 6) |
| Pre-HCT Lansky/Karnofsky performance score (n, %) | |||
| <90% | 145 (15) | 69 (17) | 33 (17) |
| 90–100% | 777 (83) | 329 (81) | 155 (81) |
| Pre-HCT Comorbidity Index (HCT-CI) (n, %) | |||
| 0 | 598 (64) | 251 (62) | 116 (60) |
| 1–2 | 195 (21) | 94 (23) | 48 (25) |
| ≥3 | 142 (15) | 59 (15) | 28 (15) |
| HCT Indication (n, %) | |||
| Acute myelogenous leukemia (AML) | 144 (15) | 44 (11) | 14 ( 7) |
| Acute lymphoblastic leukemia (ALL) | 183 (20) | 69 (17) | 31 (16) |
| Chronic myelogenous leukemia (CML) | 18 ( 2) | 7 ( 2) | 3 ( 2) |
| Myelodysplastic Syndrome/Myeloproliferative Disorder (MDS/MPD) | 69 ( 7) | 35 ( 9) | 24 (13) |
| Hodgkin lymphoma (HL) or Non-Hodgkin lymphoma (NHL) | 33 ( 4) | 12 ( 4) | 8 ( 4) |
| Severe aplastic anemia | 61 ( 7) | 30 ( 7) | 12 ( 6) |
| Inherited abnormalities erythrocyte differentiation or function | 123 (13) | 61 (15) | 26 (14) |
| Severe Combined Immunodeficiency (SCID), other immune disorders | 129 (14) | 56 (14) | 31 (16) |
| Inherited disorders of metabolism | 66 ( 7) | 31 ( 8) | 10 ( 5) |
| Histiocytic disorders | 80 ( 9) | 40 (10) | 20 (10) |
| Other | 32 ( 3) | 19 ( 5) | 13 ( 7) |
| Graft source (n, %) | |||
| Bone marrow | 527 (56) | 225 (56) | 111 (58) |
| Peripheral blood | 126 (13) | 68 (17) | 34 (18) |
| Umbilical cord blood (UCB) | 283 (30) | 111 (27) | 47 (24) |
| Donor type/matching (n, %) | |||
| Related donor (HLA-matched) | 168 (18) | 59 (15) | 31 (16) |
| Related donor (HLA-mismatched) | 53 ( 6) | 28 ( 7) | 11 ( 6) |
| Unrelated donor (HLA-matched) | 257 (27) | 116 (29) | 54 (28) |
| Unrelated donor (HLA-mismatched) | 137 (15) | 68 (17) | 34 (17) |
| Umbilical cord blood donor (HLA-matched) | 54 ( 6) | 24 ( 6) | 12 ( 6) |
| Umbilical cord blood donor (HLA-mismatched) | 210 (22) | 83 (21) | 34 (18) |
| Other/Unknown | 56 ( 6) | 26 ( 6) | 16 ( 8) |
| Donor/recipient sex match (n, %) | |||
| Male-Male | 303 (32) | 140 (35) | 61 (32) |
| Male-Female | 193 (21) | 87 (22) | 39 (20) |
| Female-Male | 243 (26) | 103 (25) | 49 (26) |
| Female-Female | 195 (21) | 72 (18) | 41 (21) |
| Donor/recipient pre-HCT CMV Serostatus (n, %) | |||
| Negative/negative | 196 (21) | 86 (21) | 34 (18) |
| Negative/positive | 246 (26) | 107 (26) | 51 (27) |
| Positive/negative | 95 (10) | 44 (11) | 20 (10) |
| Positive/positive | 272 (29) | 122 (30) | 65 (34) |
| Unknown | 127 (14) | 45 (11) | 22 (11) |
| Conditioning regimen (n, %) | |||
| Busulfan/Cyclophosphamide ±others | 255 (27) | 110 (27) | 52 (27) |
| Busulfan/Fludarabine ±others | 65 ( 7) | 29 ( 7) | 14 ( 7) |
| Busulfan/Melphalan ±others | 18 ( 2) | 8 ( 2) | 4 ( 2) |
| Melphalan/Fludarabine ±others | 183 (20) | 88 (22) | 40 (21) |
| Total Body Irradiation (TBI)-based | 358 (38) | 144 (36) | 73 (38) |
| Immunosuppression only | 41 ( 4) | 16 ( 4) | 5 ( 3) |
| Other or unknown | 16 ( 2) | 9 ( 2) | 4 ( 2) |
| Serotherapy use (n, %) | |||
| Antithymocyte globulin (ATG) and/or alemtuzumab | 624 (67) | 289 (72) | 128 (67) |
| No ATG or alemtuzumab | 312 (33) | 115 (28) | 64 (33) |
Footnotes: The following variables had missing data for PICU admissions 1, 2, and 3, respectively: Lansky/Karnofsky score (n=14, 6, 4); HCT-CI (n=1, 0, 0); donor type/match (n=1, 0, 0);); donor/recipient sex match (n=2, 2, 2). All other missing data are noted in the table above.